Literature DB >> 27826614

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Emilie Bousquet1, Allison Zarbo, Emilie Tournier, Christine Chevreau, Julien Mazieres, Mario E Lacouture, Vincent Sibaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27826614      PMCID： PMC5545893          DOI： 10.2340/00015555-2566

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  8 in total

1.  PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.

Authors:  John Dulos; Gregory J Carven; Susan J van Boxtel; Sabine Evers; Lilian J A Driessen-Engels; Willemijn Hobo; Monika A Gorecka; Anton F J de Haan; Peter Mulders; Cornelis J A Punt; Joannes F M Jacobs; Jack A Schalken; Egbert Oosterwijk; Hans van Eenennaam; Annemieke M Boots
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

Authors:  Natsuko Matsumura; Mikio Ohtsuka; Nobuyuki Kikuchi; Toshiyuki Yamamoto
Journal:  Acta Derm Venereol       Date:  2016-02       Impact factor: 4.437

3.  Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.

Authors:  Timo Buhl; Mathias Sulk; Pawel Nowak; Jörg Buddenkotte; Ian McDonald; Jérôme Aubert; Isabelle Carlavan; Sophie Déret; Pascale Reiniche; Michel Rivier; Johannes J Voegel; Martin Steinhoff
Journal:  J Invest Dermatol       Date:  2015-04-07       Impact factor: 8.551

Review 4.  Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Authors:  Vincent Sibaud; Nicolas Meyer; Laurence Lamant; Emmanuelle Vigarios; Julien Mazieres; Jean Pierre Delord
Journal:  Curr Opin Oncol       Date:  2016-07       Impact factor: 3.645

5.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

6.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Authors:  Lars Hofmann; Andrea Forschner; Carmen Loquai; Simone M Goldinger; Lisa Zimmer; Selma Ugurel; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Ioannis Thomas; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling
Journal:  Eur J Cancer       Date:  2016-04-13       Impact factor: 9.162

Review 7.  Rosacea: The Blessing of the Celts - An Approach to Pathogenesis Through Translational Research.

Authors:  Bodo C Melnik
Journal:  Acta Derm Venereol       Date:  2016-02       Impact factor: 4.437

Review 8.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Authors:  V R Belum; B Benhuri; M A Postow; M D Hellmann; A M Lesokhin; N H Segal; R J Motzer; S Wu; K J Busam; J D Wolchok; M E Lacouture
Journal:  Eur J Cancer       Date:  2016-04-01       Impact factor: 9.162
  8 in total
  1 in total

Review 1.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.